From Business model to Business model portfolio in the european biopharmaceutical industry by Valérie Sabatier et al.
 
 
FROM BUSINESS MODEL TO BUSINESS MODEL PORTFOLIO IN 
THE EUROPEAN BIOPHARMACEUTICAL INDUSTRY 
1 GAEL UMR INRA/UPMF, 1215, F-38000 Grenoble, France 
2 Grenoble Ecole de Management, F-38000 Grenoble, France 






At the crossroad of firm’s core competencies and of the anticipations of 
consumers’ needs, the business model approach complements corporate and 
business strategy approaches. Firms combine several business models 
simultaneously to deliver value to different markets, building a portfolio of 
business model. For managers, business model and business model portfolio 
are particularly useful to address customer’s needs and organisational 
capabilities of the firm. They also emphasise how the initial core competency 
of the firm can be extended or redeployed to increase the rent. Business 
model portfolio describes the firm’s strategy to balance time-to-market, 
revenue stream, risk and interdependencies. It conceptualises firm 
diversification within the same industry to generate and capture rents. They 
finally describe two generic dimensions: core competence extension to enlarge 
the market and to address additional customers and core competence 
redeployment to serve similar market with the same core competence. 
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INTRODUCTION 
Original business models emergence in new industries and become rapidly iconic. 
Those of firms that have shaped the biotech industry (such as Millennium, Celera 
Genomics or Genentech) revolutionised the environment by inventing unprecedented 
ways to bridge upstream research, venture capitalists and large firms. However the 
most successful biotech companies have generated revenues by implementing several 
different business models simultaneously to serve different customers. But the 
portfolio of business models underlying these success stories have been generally 
hidden by the most emblematic model. Many firms manage a portfolio of business 
models to develop the market value of their core competencies and to generate 
revenue streams to balance time-to-market pressure, risks, interdependency and 
expected returns. 
The article examines the biopharmaceutical industry (i.e. pharmaceutical and 
biotechnology companies) to analyse how biotech firms bridge core competencies 
and business strategies to develop business models. It argues that firms can combine 
different business models to deliver value simultaneously to different markets. Teece 
[1] defines a business model as the ‘way in which the business enterprise delivers 
value to customers, entices customers to pay for value, and convert those payments to 
profit’, and we define a portfolio of business models as the range of different ways a 
firm delivers value to its customers to ensure both its medium term viability and 
future development. Using four in-depth case studies we explore how biotech firms 
use different business model designs to generate added value and profit from their 
core competencies, and balance time-to-market, risks, interdependency and expected 
returns to create medium term value and longer term viability by organising and 
combine these models at the firm’s corporate business architecture level.  
The article contributes to current learning in three ways: first of all, it positions the 
notion of ‘Business model’ as an intermediary concept bridging firms’ core 
competencies and business strategy. Second, it introduces and discusses the notion of 
a portfolio of business models as a way to articulate and finance the firm’s activities 
in the medium run and to ensure idiosyncrasy to protect its future health. Third, it 
analyses how young firms manage to build simultaneously a short term business and 







































The first part of the article explores the relationship between core competencies and 
business models, i.e. ways to create and capture value based on core competencies. 
The data and methodology section then describes the four case studies of firms and 
their six business models, while the third section discusses management of a business 
model portfolio.  
FROM BUSINESS MODEL TO BUSINESS MODEL PORTFOLIO  
Fab-less, e-commerce, commercialisation of science, two sided markets: these new 
labels describe new ways to organise activities within firms and to reposition 
businesses to add value for customers and to generate profit for the firm. All firms 
implement business models, and many implement several simultaneously to deliver 
value for different categories of consumers and to balance revenue stream, risks and 
interdependencies with other actors. At the corporate level, firms may manage such 
portfolios of business models to generate value from their core competencies to 
address different customers. We first discuss the notion of the business model, 
considering its two fundamental dimensions: as a concept and as a tool. Business 
models are then characterised by four criteria (time-to-market, risk, 
interdependencies and expected returns). The section then introduces the concept of 
the business model portfolio as combining these four criteria to provide the firm with 
a sustainable revenue stream.  
The Business Model – a Bridge between Business Strategy and Core 
Competences 
The concept of business model is an intermediary concept between core 
competencies and business strategy, linking internal appraisal of organisational 
capabilities and the strategic positioning on evolving markets. Core competencies (or 
core capabilities) refer to a firm’s fundamental ability for undertaking specific 
activity, to create a value proposition for the ultimate customer or to deliver that 
value more efficiently. Hamel and Prahalad [2] argue that capabilities must be 
appraised in comparison with those of other firms, while Leonard-Barton [3] defines 
capabilities as core ‘if they differentiate a company strategically’. By articulating 







































their uniqueness and generate profit by delivering value to customers and 
transforming value into profit. Business model connects core competencies with 
market and customers. A firm’s core competences condition its range of possible 
activities, because it determines which pathways can be opened where it can add 
value. They are the basis of its business logic, which is then deployed in terms of 
activities to build up a business model. 
Business model and business strategy are deeply interrelated. Teece [1] describes 
business model as ‘deep truths’ about customers and their wants and needs. The 
entrepreneurs figure out what customers want and ways to satisfy them, by 
articulating those needs and matching them with technological possibilities and 
relevant organisation. Business strategy is a key component of the competitive 
strategy analysis which intends to isolate mechanisms to maintain the competitive 
advantage [4] and idiosyncratic nature of firm activity, while business model focuses 
on a specific activity. As business strategy, business model does not cover the entire 
company, and firms may be involved exploiting several business models. The 
concept of business model covers not only the firm’s interaction with the customers 
but also how it organises to benefit from the value delivered. Business model bridges 
the internal appraisal of core capabilities to understand how the firm builds its 
uniqueness in the combination of resources and business strategy, which studies how 
firms create and maintain competitive advantage. The concept of business model 
articulates the creation and value delivering for the customer, with the organisational 
capabilities of the firm to differentiate strategies [5]. 
The Business Model as Practical Tool for Managers 
Morgan and Baden-Fuller [6] argue that business models are not only a concept but 
also a practical tool for managers. As in economics, models are used in management 
to make up for the lack of knowledge, as a tool to inquire into how firms work, and to 
figure out relationships between their different elements so as to imagine how they 
might work. Business models illustrate relations between value creation and value 
capture activities for strategists, questioning existing value chains, and articulating 
possible opportunities for core competencies within value chains. 
This can be particularly valuable when industries change rapidly. As an industry 







































specialization of inputs and outputs and leading to improved efficiency and greater 
speed to market [7], and Schweitzer [8] has identified this disintegration of the value 
chain as offering opportunities for new business models. Norman and Ramirez [9] 
also propose that exploding the rigid value chain into a constellation of actors can 
allow it to be reconfigured; generating new ways to create value and leading to 
contestable markets [10]. Studying the origins of the biotech industry, McKelvey [11] 
considered the early stage strategy of Genentech, pointing out the de-integration of 
the value chain in the pharmaceutical industry during the 80s. The introduction of 
biotechnologies has opened up fresh opportunities for new entrants to propose 
alternative business models, to differentiate their offerings and to deliver added value 
to customers.  
The first category of the Business Model as a tool deals with the production of 
newness, technological innovation or in ways of doing business. New technologies 
may require new business models to capture value, as in the biotech industry where 
scientists have been able to create value from the production of scientific results, 
extending the existing pharmaceutical industry value chain backwards towards basic 
scientific research. Thus the business model can be a leverage tool to question the 
existing value chain and to identify (new) high added value positions in the value 
chain. Or the ‘newness’ may involve new ways to deliver existing technologies: the 
advent of the Internet has changed the existing value chain of computer production 
and resellers by creating direct communication between producers and consumers 
[12], as was the case, for example, with Dell, when direct internet selling enabled 
Dell to both enhance the value proposition for its consumers and the value capture 
opportunities for the firm.  
The second category of tool deals, with the dilemma of rent creation and 
appropriation. Different actors or firms are involved in the value creation process, all 
of which seek to generate rents from the value created which, (as Pisano [13] and 
Durand et al. [14] point out) inevitably generates tensions. In the biopharmaceutical 
industry, where firms develop new drugs and new techniques based on upstream 
research, those closer to the markets and to customers are better positioned to capture 
rents. Most of biotech SMEs have not been able to capture the value they anticipated, 
and rent appropriation levels are lower than expected. As business models focus on 







































value creation and rent appropriation action. When markets seem incontestable, 
incumbents dominate the competition and value-chain positions seem to be ‘locked’, 
thinking in terms of business models offers a way to re-establish contestability by 
inventing new ways to compete, be they alternative ways to deliver products or 
services, or by developing new technological innovations or adopting new positions 
in the value chain.  
Four Criteria to Characterise Business Models 
Strategists and strategic authors have tended to characterized business models by 
pointing out ‘polar’ positions: service oriented firms with short time to market and 
low expected returns versus product oriented  firms with longer times to market and 
high expected returns; [15] [16], alliances versus final consumers [17]; 
commercialization of science as intermediary services versus commercialization of 
products; direct on-line commercialization versus shops [18] [19], Chesbrough and 
Rosenbloom [4] and Voelpel et al. [20]. However, when we review the list of criteria 
used to characterise business models, we can identify four dimensions as 
synthesizing the previous works on high tech business models: time to market, 
technological/financial risks, interdependencies amongst actors and expected returns.  
Time to market characterises how and when a product or service reaches the market. 
It influences the business logic and is one of the primary factors in establishing 
competitive edge [21]. Strong market pressures tend to force firms to reduce their 
R&D time horizons to lessen their time to market [22]. Time-to-market also 
determines the firm’s ability to finance its day-to-day activities before cash can be 
generated. Cash is burnt before product or service launch to market: if times-to-
market are long, firms’ activities must be funded by their other activities, or by 
venture capital. Time-to-market also affects appropriation levels – investors 
financing firms involved in R&D will appropriate part of the eventual rents as their 
returns, and their slice of the action will increase the longer the product or service 
takes to come to market.  
Risks also affect the firm’s business logic, and have both technological and financial 
dimensions [23]. The more radical the innovation, the more the firms runs the risk 
that, in the end, it will have nothing to take to market that time, energy and reputation 







































future activity, or to repay investors. In the case of the biopharmaceutical industry the 
technological dimension also concerns drug failure: drug may fail after early or 
advanced clinical trials. Risks are also closely linked with the time frame required for 
ramp-up – longer timescales heighten both dimensions of risk.  
Interdependencies with other organisations are related to the levels of specificity of 
the firm activity. Following Afuah and Utterback [24] work about industry life cycle, 
the power of suppliers is relatively low during the emergence phase as specific assets 
have been developed. As the market increases and firm specificity grows, its relations 
with its suppliers and producers (and even consumers) will increase, and it will adopt 
strategic behaviour and adapt its business model to manage these interdependencies. 
When interdependencies are high and the firm needs additional competencies to 
perform its activity, alliances may be formed, complicating both its control of the 
activity and its ability to appropriate rents. When its exchanges with other actors 
remain non-specific, interdependencies are lower and the firm is better position to 
appropriate the generated rent. 
Expected Returns are the anticipated level of value generated by the activity, and the 
promises made by the firm to its shareholders in terms of the return they can expect 
on their investments. The level of the firm’s returns will depend upon the size of the 
targeted market, the amount of investment and the degree of its success in 
appropriating rents.   
Any business model can be characterised on these four dimensions, which are all 
interrelated. The drug development business model requires usually long investment 
before the launch on the market; it is highly risky and often requires firms to ally to 
finance and pursue their activities, and such development activity is only possible 
because expected returns are very high. At the opposite end of the scale, a service 
business model is characterised by shorter time to market, lower investment needs 
and smaller expected returns, which can enable the firm to carry through 
development internally. At the corporate level, firms often develop several business 
models simultaneously to balance these four characteristics and run multiple 
activities over on the medium term, the returns from some financing the others. To 
analyse how firms organise their activities at the corporate level, we develop the 
concept of business model portfolio building on the literature about strategic business 







































Portfolio Display, etc.) and on the management of risks in corporate innovation [25]. 
Business Model Evolution in the Biopharmaceutical Industry 
The biopharmaceutical industry has been very inventive in terms of business models. 
The biotech industry has been the setting for much development in the 
commercialisation of science, leading to the increasing role of university patenting 
[26]. and has also seen value chain de-integration opening up many opportunities for 
developing new activities.  
But it is also one where promises have been so high for so long, but where results 
have remained far below expectations [13, 27]. Firms’ managers - and the industry as 
a whole - promised to shorten drug development process, from heuristic to rationale 
drug development. Biotechnology promised personal medicine and affordable drugs 
for patients, personal genetic diagnostics and increased prevention capabilities for 
genetic diseases, and big returns on investments for biotech firms and investors. But 
after almost thirty years, Pisano has shown how the industry’s structure is flawed: 
‘islands of expertise’ need to be brought together to develop a medicine; while 
scientific knowledge is being created, new drugs discovered and process 
development improved, appropriating rents remains problematic [14]; and despite all 
the industry’s explorations and experiments with new business models, none has yet 
appeared as a dominant design. 
In the modern sense of biotechnology, the industry appeared in the mid 1970s as the 
development of genetic engineering and monoclonal antibodies disrupted the 
traditional drug development process that was essentially based on the synthetic 
organic chemistry heuristic [27]. The core competences of pharmaceutical firms were 
their accumulated know-how and their access to patients to perform trials. The first 
wave of biotech firms made their way to the market via strong partnerships with 
pharmaceutical companies, and today are the two are often integrated vertically, with 
most biotech firms specialising in one or two elements of the classic drug 
development value chain (fig 1).  
Figure 1: The traditional drug development value chain 
 







































five well known (usually consecutive) steps leading to the market: research and drug 
discovery, preclinical studies (animal tests), phase I (early human clinical trials), 
phase II (medium-sized human tests) and phase III trials (large human tests). 
However, since 2000, the value chain has been de-integrated, and a new form of 
networked industrial structure involving highly specialised actors is emerging [28]. 
Large pharmaceutical firms fill gaps in their R&D pipelines and research portfolios 
by collaborating with smaller firms, buying or co-developing drugs at any stage of 
development [27]. And biotechnology developments have focused not just on 
products, but also on specific and high value added service elements. 
DATA COLLECTION AND ANALYSES 
This section describes the generic core biotech industry competencies and presents 
two levels of analysis – the business model and the firm. Case studies of European 
biotech firms and their business models are examined to analyse the business models 
firms employ to put their core competencies into action to deliver value, so as to 
illustrate how they build business model portfolios at the corporate level. Data 
collection was organised to gather data at two levels: business models and firms. 
First,  sixteen experts of the European biopharmaceutical industry were interviewed 
to map out the core competencies along the drug development value chain and 
understand the basis underlying today’s business models. Second we conduct four 
case studies of European biopharmaceutical SMEs to gain fine grained analysis of 
business models portfolio, showing how young companies employ different models 
to optimise the allocation of their resources.  
Three Core Competencies 
Experts have identified three core competencies in the contemporary biotech industry 
(for more details see appendices 1 and 2):  
  The traditional competence of drug discovery, which follows the conventional 
drug development route illustrated above, focuses primarily on the process 
new drug development by creating molecules with the potential to be 







































focused on the discovery and ownership of candidate drugs;
 
  The architecture and recombination of knowledge from the biotech and 
biopharmaceutical industries, in which firms reorganise their knowledge to 
detect opportunities aiming to mobilise, combine or benefit from external 
knowledge. This competence focuses on the ability of the firm to orchestrate 
knowledge from its partners rather than on its own ability to develop new 
drugs, and may involve value chain reconfiguration; 
  The processes optimization competence. As biotechnolgies matures, costs 
become more significant, and the more efficient industrialisation of services, 
R&D or production processes, or the improvement of linkages between the 
two, become more important.  
Table 1 evaluates the characteristics of the different business models based on these 
core competencies (for more details about the evaluation of the characteristics see 
appendix 3). 
Table 1: General characteristics of biopharmaceutical business models 
Core Competence  Time-to-
  market 
Risk  Interdependenc
y with other 
firms 
Expected 
  returns 
Drug Discovery  Long  High  High  Very High 
Knowledge 
Architecture 
Medium  Medium  High  High 
Process Optimisation  Short  Low/Medium Low  Low 
 
The drug discovery core competence is characterised by a long time needed to work 
through the development route value chain, levels of risk and interdependency are 
high, because outcomes cannot be guaranteed but high levels of financial investments 
will be required whether the searches end in success or failure and the focal firm will 
need external expertise - but expected returns can be very high: launching a 
successful new drugs onto the market will yield allow good returns and margins. The 







































and while interdependency with other firms is high, so are the expected returns. The 
process optimisation core competence generally involves short times to market with 
low or medium risks and requires few interdependencies, but does not promise high 
returns. Based on each core competence, firms adapt, design and amend business 
model to improve their characteristics: reducing time-to-market for drug discovery, 
managing interdependencies and risks for knowledge architecture more effectively 
and increasing the expected returns to process optimisation.  
Business Models at the Firm Level 
To describe business models and they are enacted within a firm, we focus on four 
case studies. As the post-2000 period has been characterised by the increasing 
specialization of business models, we limited our sample to firms founded since 
2000. We employed the technique of searching for polar types, where an important 
guideline is to select cases that contradict patterns noted in prior cases study [29]. So 
we sought companies with business models that differed substantially from the fully 
integrated pharmaceutical company business model [28] that has been studied often. 
Four European biopharmaceutical companies suited these criteria and agreed to be 
part of the study.  
Data collection began with meeting the founders of the company and questioning 
them about the company’s history, its activities and markets. Each interview lasts at 
least two hours and generated an overall view of the company’s bundle of activities. 
(A high level of confidentiality was assured to secure access to strategic information.) 
The second phase was dedicated to analysing documents and cross-referencing 
internal sources against information from specialized press and website sources. The 
third phase comprised in-depth individual interviews lasting an hour and half with the 
CEO, chief scientific officer (CSO) and chief financial officer (CFO) of each firm, 
focusing on the financing model, the structure of costs, investments, scientific 
challenges, times to market and the revenue model. We also asked about the firm’s 
partners and their levels of involvement, and about intellectual property issues around 
the firm’s products or services, parameters which help us determine the company’s 
business models and the way its portfolio is managed.  
We first analysed core competences in action i.e. how firms designed effective 







































business model based on the three generic core competences as well as the firm’s 
positioning on  the value chain.  
The second level of analysis was of the firm as a whole, to discover how it combined 
its different business models to implement its overall strategy. Three of the four firms 
were managing a portfolio of different business models, while the other replicated the 
same business model in order to maximise its value proposition: we study how each 
enacts its business models to generate and appropriate rents. 
Analyses of Four Cases  
OphSmart is a small company of thirty people founded in 2005 which develops a 
pipeline of products all focusing the ophthalmology therapeutic domain. OphSmart 
has two core competencies: drug discovery and knowledge architecture. In the drug 
discovery realm, OphSmart specialises in upstream collaborations with universities to 
renew its own pipeline. In terms of knowledge architecture, OphSmart seeks to 
shorten drug development times by repositioning drug candidates in ophthalmology. 
These drugs are bought from other companies. Then OphSmart manages a network of 
firms to develop the molecules: it does not invest in manufacturing or laboratories, 
OphSmart externalises every step of the drug development. It therefore runs three 
interrelated business models concurrently: collaboration with universities to discover 
molecules; repurposing of existing molecules to its therapeutic domains and 
organising networks to form a virtual company. Each time, the business logic is 
based on a dense network of contacts, built up over the projects and over the previous 
deep involvement in the industry of the management team.  
Emics is a small company run by a team of three people which, since its founding in 
2003, has specialised in one therapeutic domain (a worldwide infectious disease) and 
is mainly focused on developing two vaccines that originated in the firm’s in-house 
scientific collaboration with an academic laboratory. Emics mobilises its core 
competencies successively: drug discovery to identify new potential vaccines, and 
knowledge architecture to orchestrate its network of partners and suppliers to develop 
its vaccines, arranging its partners’ different competencies to form a virtual vaccine 
company.  
OpteX is a company of fifty employees, founded in 2000 which specializes in 







































competencies: process optimisation and knowledge architecture. At the beginning the 
company proposed one business model based on process optimisation: the 
technology platform, and developed know-how about optimisation of research and 
drug production processes. In 2004 it offered a complementary service - based on the 
same core competence but with a different value proposition – by becoming a 
contract manufacturer, producing specific molecules for pharmaceutical companies. 
While the therapeutic domains addressed may be different, the technology underlying 
its two main business models - technology platform and contract manufacturing - 
remains the same. In 2008 OpteX started marketing technology brokering services, 
based on its new knowledge architecture competence that was building on its 
network of partners, clients and suppliers.  
Betwin was founded in 2007 and employs a staff of five. Its core competency is 
knowledge architecture: the company buys a drug candidate at early development 
stages (first proof of efficiency or preclinical trials), then develops it through an array 
of partners and suppliers and resells the drug candidate after later trials (for example 
after phase II). Betwin has bought three molecules in different therapeutic areas in 
the past two years, replicating the same business model each time.  
The analysis of the four companies and of their six business models shows how firms 
build on their core competencies and organize their activities to generate rents. The 
combination of business models within portfolio balance the firm activities and its 
revenue streams. 
ADAPTING BUSINESS MODELS AROUND THREE CORE COMPETENCIES  
The relationships between core competencies and business models are discussed first, 
followed by descriptions of how firms organize their business model portfolio. 
Drug Discovery Core Competence 
Such firms share risks with partners and aim to shorter the time to market by using 
business models different to the traditional business model for drug development. 
Collaboration for Discovery model: to deal with the high risk/high time-to-market 
drug discovery model, OphSmart and Emics develop alternative sourcing of 







































companies in long term research collaborations to share the risk and speed up the 
process of carrying out extreme upstream research to develop new drugs.  They limit 
their investment and risk by specialising in upstream research and early discovery 
phases to, and sign exclusive licences with their discovery partners to appropriate 
value. Time to market is shortened and investments are recouped by selling on drug 
candidates to partners lower in the value chain. Although the risk of drug failure 
remains, partnering allows firms to lower its own risk for the company. 
Interdependency is high - as the partner is a key to accessing knowledge - but 
expected returns, based on drug selling, are high.  
Knowledge Architecture Core Competence  
Firms change the architecture of knowledge in the biotech industry. They develop 
virtual, repurposing or brokering activities to rearrange knowledge and benefit from 
it. Virtual firms focus on drug development activities, but firms have no laboratory or 
manufacturing capabilities and outsource almost everything, coordinating research 
that is actually performed by its partners. The business logic and source of value of 
this model are in orchestrating a network to develop a drug product, with product 
price and time and cost savings as the means of capturing value. Such virtual 
activities speed up the process of drug development and promise a medium time to 
market. As research execution is shared amongst the different partners, risks are 
medium as less investment is required than in an integrated company, although - of 
course - this model is still sensitive on drug failure. Interdependency with other firms 
is high because the core activity of virtual firms depends entirely on its partner 
alliances for access to knowledge, equipments and markets. The returns expected to 
successful drug development are high.  
Repurposing activities consist on choosing a molecule in development or on the 
market for one therapeutic domain and repositioning it towards a new therapeutic 
domain. Choosing already developed molecules allows these firms to re-start the 
product development chain without having to go through the discovery phase. The 
value is created by the detection of the opportunity and the development of the 
product, and captured from time and costs savings as well as from product sales. The 
time-to-market is short to medium because the safety and efficacy of the repurposed 







































clinical and clinical trial stages are shorter. Risks are medium because the probability 
of failure is low, but drug development still requires investments for later trials and 
marketing. Interdependency with other firms is important as it is key to detecting 
opportunities, and successful alliances are necessary for taking the drug to its new 
market development: thus dividing the intellectual property rights can become a 
central (sometimes difficult) issue. These companies have a product that can go to the 
market quickly: investments can be recouped and cash starts flowing. Expected 
returns are high.  
Brokering activities establish linkages between technologies and firms which are not 
yet connected. In this context it refers to the detection of a molecule in one 
company’s pipeline that could interest another company, making the connections and 
managing the transaction between the two firms [30]. The market is not the drug 
market but biopharmaceutical firms. Detecting the opportunity is the source of the 
value creation, and value is captured when the technology broker receives a 
commission. So the time-to-market is very short and the risks are low (drug failure 
has no impact and few investments are needed). Interdependency is high, as it is the 
basis of the company’s business, but, clearly, expected returns are low compared to 
those of a product company. 
All these activities are based on knowledge architecture core competencies. They are 
undertaken by small firms with highly skilled and well informed scientists who are 
able both to combine different technologies, therapeutics and also to negotiate 
agreements with CEOs: Emics manages the development of two vaccines with only 
three people; OphSmart manages four repurposed drugs and four drug candidates 
with thirty people, Betwin manages three product with a team of five; OpteX 
management team connect previous clients and partners. Activities are performed at 
the margins and accessing the value chain through partners, sourcing innovation from 
other firms or connecting companies together to make deals. In these business 
models, firms articulate knowledge in original ways to produce new drugs or to offer 
new services that are unique on the market. Comparing to the traditional business 
model of drug discovery these business models reduce time to market and risks: 
managing an array of partners brings expertise at the very needed moment and 







































Process Optimization Core Competence 
The core competence of process optimisation deals with optimising drug 
development processes. R&D or production processes can be made more efficient, or 
linkages between the two improved. Optimisation concerns services, research tools or 
production. In our firm we found two business models built on this core competence.   
Technology platform activities include engineering and technological developments, 
molecule optimisation, screening, etc., and generally focus on the early drug 
development phases. They are many forms of platforms (such as open technology 
platforms, proprietary platforms, etc.) but broadly speaking they provide 
technological developments through service contracts or act as co-developers at some 
product development steps. This technological development activity creates value, 
which is then captured through the price of the service or the success of the drug or 
technology co-developed. The time-to-market is short to medium, and risks are low 
(in the simpler service case) or medium for co-development activities. 
Interdependency and expected returns are also low or medium, again depending on 
the form (contract or co-development partnership) of the activity.  
Contract manufacturing organisations (CMO) is a business model which is based on 
optimisation processes for the production of preclinical, clinical and final batches for 
other actors of the value chain. 
Activities in business models based on process optimisation are not core to the main 
value chain, but provide services for value chain actors. Firms provide the same kind 
of actions for any product, corresponding to the ‘layer player’ archetype [8]. With 
shorts time to market these business models generate cash in the short term.  
Table 2 presents the adapted business models based on the three core competencies in 
the biotech industries and observed in practice. Each of the business models improves 
at least one of the criteria: reducing risk for collaboration in discovery, maintain high 
returns with limited risks for business models based on knowledge architecture and 
shortening time to market for optimisation business models. All the firms have 
developed different activities within the same industry, organising their business 
models to align their organisational capabilities to address specific customers and to 








































Table 2: Adapted business models  
       Criteria 
Business  Model  












Discovery  Long  Medium  High  High 
Repurposing  OphSmart  Knowledge 
architecture 
Medium  Medium  High  High 





Medium  Medium  High  High 
Technology 
Brokering 
OpteX  Knowledge 
architecture 
Short  Low  High  Low 
Technology 
Platform 










OpteX  Process 
Optimisation 
Short  Medium  Low  Medium 
 
BALANCING A BUSINESS MODEL PORTFOLIO 
In practice these four small European biopharmaceutical companies may use more 
than one competence to position themselves on the value chain and may thus employ 
several business models. The business architectures of OphSmart, Emics and OpteX 
involve managing several business models simultaneously, with two core 
competencies in each case. A key issue for these companies is to try to moderate time 
to market and risks in order to attract investors, redeploying or extend the same 
business logic towards additional costumers. Betwin is the only one which reuses the 
same core competence into different markets. 
OphSmart’s portfolio mixes long and medium times to market, medium and low 
risks, high and low needs for alliances and high expected returns. Its three business 
models enable it to balance the time to market, risks and interdependency to keep 
returns on investment high. Its activities are also linked: whether a molecule is 
repurposed or discovered in-house, it will be developed via the virtual development 
business model. OphSmart redeploys its core competencies to capture value at 
different stages of the value chain. Emics runs two business models based on one 
core competence each, its two core competences, allowing it to balance time to 







































discovery-based business model), they are lowered by its knowledge architecture 
competence. OpteX’s business models do not promise high returns, but times to 
market are short and risks low, allowing it to generate short-term rents successfully. 
OpteX originally used its core process optimisation competence to manage two 
business models that were internally coherent -the technology platform and contract 
manufacturing organization (CMO) activities followed the same sequential drug 
development steps – and re based on the same production optimisation business 
logic. But the firm also detected the opportunity of technology brokering on the value 
chain using the strong network of clients developed via its original business models - 
they naturally became both sources and customers for its new technology brokering 
model, with OpteX acting as a link between them. OpteX was able to align this new 
activity coherently both with its business sector and with its current activities. Once 
its three business models are stabilized the company will be able to take more co-
development risks in its technology platform business model.  
Finally, Betwin has one business model which it has replicated continuously, which, 
because it focuses on new opportunities created by intermediary markets, assures it of 
a medium time to market with medium risks and promises high returns to investment. 
Betwin’s founders recognised this new opportunity on the value chain, and adapted 
their business logic specifically to match this profit zone. Betwin has developed 
capabilities to detect molecules and to organise networks to deliver them. So the firm 
is organized on a virtual business model to buy early developed molecules to create 
value for its customers. 
These four companies show that business models can be balanced to insure short or 
medium time-to-market, which is important as it is difficult for small companies to 
survive the long period – of maybe twelve years - without turnover and profit 
involved in longer-term models. Long time lags between investment and the first 
generation of turnover can often lead to rejection by investors, whereas being able to 
promise mid-term rents can reassure shareholders that they will see a return on their 
investment within five years.  
Table 3 sums up each firm’s business model portfolio, and emphasises the 
relationships between core competencies and business models and different ways to 







































Table 3: Business model portfolios  





















2 Virtual,  
3 Repurposing  
1 Collaboration 
for Discovery,  












at different stage 
of the value 
chain 
Complementary 
at different stage 
of the value 
chain 





Identical  Identical  Identical (or close) Different 
 
Firms invest in different business models to limit the level of risk and to speed up 
time-to-market for part of their activities. Firms with drug discovery as their core 
competence need to benefit from additional competencies to develop new drugs, so 
they are often involved in dense networks to perform their activities, and thus need to 
be able to manage interdependencies effectively. For firms investing in knowledge 
architecture as a core competence, their activity is to manage linkages with other 
actors, and they are thus also highly interdependent. Finally, firms that invest in 
optimisation, and whose business is to optimise other actors’ production processes, so 
they, too, depend on others. These business model portfolios portray an interesting 
link between with risk and time-to-market: while product companies promise a high 
value, alternative business models are used to balance risk and time-to-market values. 
So (compared to fully integrated pharmaceutical companies) these small firms have 
found ways to promise high value, medium risk and acceptable times-to-market. 
DISCUSSION  
  A business model can be defined as standing at the intersection between 
management expectations about market needs and how they design their activities 
and organise their capabilities to meet them, by linking core competencies and 







































firm to meet different consumers’ needs and build the idiosyncrasy of the firm’s 
bundle of activities. The concept of business model portfolio to balance risk, revenue 
stream and interdependencies is discussed, as positioned between business strategy 
and corporate strategy.  
Strategies with Business Model Portfolio 
Business models bridge management’s expectations about customer needs and their 
core competencies. In maturing industry, specialisation and division of work within 
the value chain create opportunities for firms to design new business models and new 
value propositions. This article argues that a core competence can be transformed in 
several business models, and shows how, in the biopharmaceutical industry, firms 
have found numerous ways to translate their core competencies into activities to 
address costumers at different stages of the value chain. The business model as a 
concept linking core competencies, the value chain and consumers’ needs can help 
promote strategic thinking from both the internal and external perspectives. 
The existence of a portfolio of business models reveals the firm’s maturity as it 
develops from the start-up phase (based on a single business model) to managing a 
more complex architecture designed to reduce risks and maintain equilibrium across 
a variety of activities. Case studies reveal that firms tend to add activities that relate 
to some aspect of their existing ventures, either based on the same core competence 
or developed to take exploit certain common technological and market 
characteristics. Firms can have one or more core competences enacted within 
different business models, reveal the coherence of their activities [31]. Different 
business models can be driven by similar business logics, when they extend the 
market niche addressed or the services or products offered to similar audiences.   
Companies may run parallel, vertical integrated business models to cover more 
sectors of their value chain, and their consecutive articulation can allow the firm to 
benefit from synergistic effects, adding more value for customers and (hopefully) 
more profit for the firm.  
 Table 3 presents the different strategic positions in portfolio of business model. The 
two main dimensions to deal with are risks and interrelatedness between business 
models, which deeply affect the organisation of the activities. On the one side, it 







































side it assesses the degree of relatedness between existing activities within the firm. 
Table 3: Balancing business models portfolio 






























































  Low expected 
returns for firms 
mainly involved in 
service activities. 




The firm addresses the 
same market balancing 
high risk business 
models based on the 
product development 
and low risk business 
models like those 
based on knowledge 
architecture 
High expected returns. 
The firm is highly 
dependent on external 





















may be turned into 







The firm is investing 
simultaneously in highly 
risky business. Based on 
diversification, such a 
strategy is too risky for 
independent firms. Only 
subsidiary companies 
may invest in such a 
strategy  
 
When business models are disconnected, running portfolio of business models 
represents a diversification of activities. If time-to-market is long, it is a highly risky 
strategy for small independent firms. If business models are related, and time-to-
market long, then the strategy is highly risky but expected returns are very high. It is 
usually the traditional core competence of drug development. To limit risks and to 
reduce time-to-market, firms run different core competences and develop business 
models based on knowledge architecture and repurposing. Business models portfolios 
built by OpteX, OphSmart and Emics balance risk and interdependencies of business 
models. They offer a range of strategic options for entrepreneurial firms - although 
young firms have limited resources, the development of a business model portfolio 
based on mobilising a few core competencies promises to reduce bother risks and 
time to market, as well as to promote medium run developments. Building and 
managing a business model portfolio has been a way for small European biotech 







































interdependencies and expected returns.  
Business models Portfolio and Corporate Strategy 
Business model and business strategy are deeply interrelated. They both focus on one 
activity and key customers. As a key component of its competitive strategy, a firm’s 
business strategy aims to identify growing markets and to position firm activities 
within those markets. Business models then describe how firms develop 
organisational capabilities to benefit from these promising markets, so connecting 
internal capabilities with ways to address market niches and costumers. Business 
models are not included in business strategy as poorly attractive industry may 
generate wonderful business models if the firm is able to better serve its customers 
than other actors. Similarly, all business models may not perform equally well in the 
same industry. Dealing with specific ways to interact with customers, business 
models offer a more detailed level of design than business strategy.  
  Similarly, business model portfolio (BMP) is not equivalent to business strategy 
which positions the firm activities on different industries, according to their relative 
attractiveness. BMP can be developed within the same range of activities, by 
extending similar business logics to additional market niches, by serving similar 
customers elsewhere along the value chain or by capturing rents on existing activities 
through the transformation of distribution channels.  
The need to understand business models and business model portfolios – as concepts 
and a tool – will intensify as start-ups and small firms increasingly become the 
cornerstones of economic development. Traditional strategic analysis, expressed in 
terms of business and corporate strategy, is poorly adapted to small ventures which 
are involved in one industry: business models can help fill the knowledge gap about 
small venture strategies. Focusing on how the firm’s organisational capabilities can 
be designed to address costumer needs, the concept of business model covers the 
coherence of activities between internal organisation and markets, and can be a way 
to emphasise how the initial activity of the firm can be extended or redeployed to 
increase the firm’s rents. A business model portfolio encapsulates the firm’s strategy 
to balance multiple activities, risks and revenue streams. It conceptualises firm 
diversification within the same industry to generate and capture rents and to balance 







































strategies: core competence extension to enlarge the market and to address additional 
customers and core competence redeployment to serve similar market with the same 
core competence.  
CONCLUSION 
A business model can be seen as an intermediary tool between corporate and business 
strategies, and defined as articulating a value proposition for an evolving value chain, 
and the way in which the firm delivers product or services to create and then 
appropriate value. A firm’s business strategy determines how it uses its resources, 
satisfies its long-run objectives, and defines the implementation of its corporate 
strategy [32]. The business model articulates both the internal and external 
dimensions, bridging between capabilities and competences, and value chains, 
markets and customers, focusing on the coherence of activity within both the industry 
and the firm.  
A biopharmaceutical company providing R&D services and production of early 
clinical trials will segment its business strategy depending on the market: e.g. 
proteins vs. monoclonal antibodies. But the business model view considers two 
business models: the contract research organization and the contract manufacturing 
organization. Although the markets are different, the activities are closely linked and 
the company will enhance its coherence and synergy effects if it manages its business 
models to benefit from these effects.   
For managers, the concepts of business models and business model portfolios are 
particularly useful to understand that firms can pursue multiple business models 
within one strategy. This meso-level analysis generates descriptions that allow 
strategists to better position the firm activities. In addition, industry matures, and its 
activities, actors and their relationship are continually evolving. To put it simply, the 
notion of the business model which articulates activities within the firm and its 
relation with customers is particularly suited to changing environment. Different 
ways may be explored, from core competence extension to duplication in other fields. 
For a firm that is deeply embedded in networks, when its frontiers are becoming 
blurred and its value chain shifting, the notion of the business model can help 







































drives an analysis of the firm that can allow it to adjust its position on the value chain 
and its mechanisms for value creation and capture. Managers who initially developed 
the concept of the business model were searching for a strategic tool that could take 
into account the problems of how to address several markets with a pertinent value 
propositions, and how to develop a flexible architecture to do business in complex 
environment. In fast changing and fast growing industries, value chains can get 
continually reconfigured, heralding the appearance of new zones of profit. With a 
business model portfolio a company can easily construct and reorganize its activities 
in coherence with both the firm and with the evolving environment. Managing a 
business model portfolio helps piloting time-to-market, risks, interdependency with 
other firms and expected returns, and can give clear indications of synergies that exist 







































Annexe 1: Interviewees  
Respondent 1 Vice-President (in charge of European activities) for one of the largest 
biopharmaceutical companies famous for its biotechnology products He has worked in 
the biopharmaceutical industry for many years, having started as a scientist thirty 
years ago in a big pharmaceutical company  
Respondent 2 Scientific Director in charge of scientific strategy of a world competitive cluster 
providing a healthcare shield against infectious diseases, and centre of excellence in 
diagnostics and vaccines.   
Respondent 3 Research Director in a National Institute of Health. Having focused for years on 
antibodies research, he runs a team looking for therapeutic targets and drug candidates. 
Respondent 4 Head of the pharmaceutical department, French Ministry of Finance and Economics, 
this respondent negotiates with biopharmaceutical companies about reimbursement 
levels and French market access conditions.  
Respondent 5 Research Director in a Centre for the Study of Drug Development, a specialist 
observer of the biotechnology industry over years and published widely in academic as 
well as managerial reviews.  
Respondent 6 CEO of European Start-up who has worked in the biopharmaceutical industry for more 
than twenty years and previously founded two other start-ups. His current start-up, 
founded in 2006, is a nanomedicine company that intends to revolutionize drug 
delivery and drug addressing.  
Respondent 7 CEO of European Start-up (founded in 2006) in parallel with his position of Research 
Director in a National Health Institute. Start-up business based on a promising 
technology for radio labelling, preclinical studies and radiopharmaceuticals synthesis; 
intending to assist other companies in strategic decisions for selecting and developing 
drug candidate molecules/biomolecules.  
Respondent 8 European Start-up Chief Scientific Officer, founder of an information technology firm 
that provides customized IT solutions for drug development or patients’ observations. 
Respondent 9 European biotechnology medium company CEO who founded his first company in 
2000 to provide propose high value added services for drug development.  
Respondent 
10 
European biotechnology medium company CEO manages a biopharmaceutical 
company dedicated to the discovery and development of products innovation for a 
specific disease.   
Respondent 
11 
European biotechnology medium company CEO who manages a biopharmaceutical 




European biotechnology medium company CSO is the co-founder of a 
biopharmaceutical company, and manages its scientific programs, collaborations and 
participations in European consortia.  
Respondent 
13 
European biotechnology medium company Chief Scientific Officer in a company 
developing vaccines having started his career in a prestigious academic laboratory.  
Respondent 
14 
European biotechnology medium company COO of a biopharmaceutical company 
dedicated to product discovery and development. He started as a scientific researcher, 
and has since been involved in the management of many companies.  
Respondent 
15 
European biotechnology medium company CFO for a product-based firm. He has 
worked in the biotechnology industry for many years and conducted two Initial Public 
Offerings in different companies  
Respondent 
16 
CFO of European biotechnology medium company European biopharmaceutical 








































Appendix 2: Extracts of interviews that helped us to determine the three core competences present on the drug 
development value chain.  
Core 
competence 
at basis of 
activity 








‘This business is about 
finding the most 
promising drug’ Resp. 6 
‘We discover and patent 
our drugs and we develop
it until phase II’ Resp. 11
‘ the company focuses on 
the development of its 
pipeline’ Resp. 1 
‘We take out a patent for 
every drug candidate’ 
Resp. 1 
‘These companies are 
doing in-house research 
and develop their drugs 
until phase I or II’ Resp. 
4 
‘We negotiate with 
companies that bring to 
market innovative drugs.’ 
Resp. 4 
‘The collaboration with 
the academics is very 
important. I collaborate 
with experts of the field 
in order to find the most 
promising approach for 
our vaccines’ Resp. 13.  
‘Discovery is the heart of 
our business’ Resp. 1 
‘We are developing drug 
candidates and this is 
what the shareholders are 
looking at.’ Resp. 16 
  
‘Those companies 
work in network and 
buy product they did 
not discover’ Resp. 2 
‘Cost is one reason to 
revisit existing drugs 
and it can be the 
centre of a business’ 
Resp. 15 
‘The technology 
broker are selling 
intellectual property’ 
Resp. 2  
‘Our company also 
proposes a catalogue 
of drug candidates’ 
Resp. 12  
‘Our challenge is to 
create a 
comprehensive 
clinical drug library to 
screen every 
neglected disease by 
2015’ Resp. 7 
‘the virtual companies 
are developing drug 




development is so 
long and so 
complicated that often 
the company who 
discover the molecule 
is not the one which 
brings it to market’ 
Resp. 4 
 
‘some technology platforms 
are quiet big in Europe and 
have found a profitable 
market segment because they 
provide very specific 
services’ Resp. 3 
‘we provide high value added 
services for drug 
development’ Resp. 9 
‘these firms propose 
advanced tools for research 
and drug discovery’ Resp. 5 
‘We are specialized in the 
process development’ Resp. 9
‘We are a company 
specialized in clinical trials 
and sell it as a service’ Res. 5
‘The companies specialized 
in safety and evaluation are 
essential’ Resp. 2.  
‘the manufacturing is an 
important activity and we are 
working with Contract 
Manufacturing Organisations 
which are only doing that’ 
Resp. 14 
‘We outsource the 
formulation because it has to 
be done by specialists’ Resp. 
10 
‘This business is about 
providing customized IT 
solutions for companies who 
are developing drugs’ Resp. 
8.  
‘We also propose specialized 
tools to follow clinical trials’ 
Resp. 8 







































Appendix 3: Classification of biotech business model characteristics 
Characteristic 
Time to market  Short   Medium *  Long  
 Completing the full drug development 
value chain takes 10 to 15 years.  
Service or 
intermediary 









s:   7+ yrs 
Risk  Low  Medium  High 
The risks depend on 2 factors:  
- Sensitivity to drug failure: if a business is 
based on the success of a drug development 
then the failure rate increase the risks (for 
one hundred drug candidate one or two 
reach the market) – low, medium or high.  
- Amount of investments: the more 
investments are necessary the more risky is 
the business model –low- medium – high. 
Risk is low if 
one of the two 
factors is low 
 
Risk is 
medium if one 








Interdependency with other firms  Low  Medium  High 
Firms may be dependent on other firms to 
access complementary competencies such as 
knowledge, skills, equipment, market 
channel, etc. 












When the core 





Expected returns   Low  Medium  High 
Expected returns are the turnovers that will 
be created by the activity. The maximum is 
the turnover produced by a blockbuster 
drug. In comparison the price of a service is 








Drugs on the 
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